High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 46, Issue 9, 2007, Pages 1128-1137

  Kratochvil, Christopher J ^a   Michelson, David ⁱ   Newcorn, Jeffrey H ^b   Weiss, Margaret D ^c   Busner, Joan ^d   Moore, Rodney J ⁱ   Ruff, Dustin D ⁱ   Ramsey, Janet ⁱ   Dickson, Ruth ⁱ   Turgay, Atilla ^e   Saylor, Keith E ^f   Luber, Stephen ^g,h   Vaughan, Brigette ^a   Allen, Albert J ⁱ  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f NeuroScience Inc   (United States)

^g Rockwood Clinic   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Dose

Indexed keywords

ATOMOXETINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 34548071916     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/chi.0b013e318074eeb3     Document Type: Article

References (10)

1. Bymaster FP, Katner J, Nelson DL et al. (2002), Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 27:699-711
2. Committee for Proprietary Medicinal Products (1997), The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. (CPMP/986/96). London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit
3. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford
4. Faries DE, Yalcin I, Harder D, Heiligenstein JH (2001), Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:39-47
5. Landgraf JM, Abetz L, Ware JE (1996), The CHQ User's Manual. Boston: The Health Institute, New England Medical Center
6. Michelson D (2004), Results from a double-blind study of atomoxetine, OROS methylphenidate, and placebo. Presented at the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 19-24
7. Michelson D, Faries D, Wernicke J et al., Atomoxetine ADHD Study Group (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83
8. National High Blood Pressure Education Program Working Group (1996), Update on the Task Force Report (1987) on High Blood Pressure in Children and Adolescents: A Working Group Report From the National High Blood Pressure Education Program. (No. 96-3790). Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute
9. National Institute of Mental Health (1985), Clinical global impressions. Psychopharmacol Bull 21:839-843
10. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA (2002), Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 30:319-323